CytoPort Biotech Secures Angel Round Funding

Recently, CytoPort (Tianjin) Biotechnology Co., Ltd., an enterprise  in TEDA, completed an angel round co-financing of nearly RMB 10 million, jointly funded by the TEDA Industrial Guidance Fund and the TEDA Daoyuan Life Sciences Venture Capital Fund. Following the completion of this financing, CytoPort Biotech will put over 3,000 square meters of industrial R&D space into use to build an integrated R&D and pilot scale-up innovation platform, advance the construction of GMP-standardized production lines, filings for Class III medical devices and innovative drugs, and accelerate the industrialization of cutting-edge bionic biotechnology.

Recently, CytoPort (Tianjin) Biotechnology Co., Ltd., an enterprise  in TEDA, completed an angel round co-financing of nearly RMB 10 million, jointly funded by the TEDA Industrial Guidance Fund and the TEDA Daoyuan Life Sciences Venture Capital Fund. Following the completion of this financing, CytoPort Biotech will put over 3,000 square meters of industrial R&D space into use to build an integrated R&D and pilot scale-up innovation platform, advance the construction of GMP-standardized production lines, filings for Class III medical devices and innovative drugs, and accelerate the industrialization of cutting-edge bionic biotechnology.

In recent years, TEDA's biopharmaceutical industry has maintained strong momentum, becoming a crucial growth driver for high-quality regional development and the key carrier for Tianjin's biopharmaceutical sector. In 2025, TEDA’S healthcare industry reached RMB 80.93 billion in the output value, with its pharmaceutical sector accounting for over 50% of the Tianjin’s total and continuously unleashing cluster effects.